Solid Biosciences Inc. Earnings Per Share, Basic and Diluted
Solid Biosciences Inc. (SLDB) reported Earnings Per Share, Basic and Diluted of -$0.22 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-04-27.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-04-27
- Solid Biosciences Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.22.
- Solid Biosciences Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.16.
- Solid Biosciences Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.17.
- Solid Biosciences Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.19.
- Solid Biosciences Inc. earnings per share, basic and diluted for fiscal 2021 was -$0.68.
- Solid Biosciences Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.70.
- Solid Biosciences Inc. earnings per share, basic and diluted for fiscal 2019 was -$2.91.
- Solid Biosciences Inc. earnings per share, basic and diluted for fiscal 2018 was -$2.25.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.22 10-Q · filed 2022-04-27 | |||
| 2021-12-31 | -$0.68 10-K · filed 2022-03-14 | |||
| 2021-09-30 | -$0.16 10-Q · filed 2021-11-03 | -$0.33 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.51 10-Q · filed 2021-11-03 | |
| 2021-06-30 | -$0.17 10-Q · filed 2021-08-16 | -$0.35 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | -$0.19 10-Q · filed 2022-04-27 | |||
| 2020-12-31 | -$1.70 10-K · filed 2022-03-14 | |||
| 2020-09-30 | -$0.44 10-Q · filed 2021-11-03 | -$0.83 derived: net income ÷ weighted average shares · filed 2021-11-03 | -$1.39 10-Q · filed 2021-11-03 | -$2.05 derived: net income ÷ weighted average shares · filed 2022-03-14 |
| 2020-06-30 | -$0.39 10-Q · filed 2021-08-16 | -$0.95 10-Q · filed 2021-08-16 | -$1.61 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$2.28 derived: net income ÷ weighted average shares · filed 2022-03-14 |
| 2020-03-31 | -$0.56 10-Q · filed 2021-05-14 | -$1.22 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$1.89 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$2.62 derived: net income ÷ weighted average shares · filed 2022-03-14 |
| 2019-12-31 | -$0.67 10-K · filed 2020-03-12 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$2.08 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$2.91 10-K · filed 2022-03-14 |
| 2019-09-30 | -$0.67 10-Q · filed 2020-11-05 | -$1.42 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$2.26 10-Q · filed 2020-11-05 | -$2.90 derived: net income ÷ weighted average shares · filed 2021-03-15 |
| 2019-06-30 | -$0.76 10-Q · filed 2020-08-06 | -$1.61 10-Q · filed 2020-08-06 | -$2.24 derived: net income ÷ weighted average shares · filed 2021-03-15 | -$2.80 derived: net income ÷ weighted average shares · filed 2021-03-15 |
| 2019-03-31 | -$0.85 10-Q · filed 2020-05-07 | -$1.48 derived: net income ÷ weighted average shares · filed 2021-03-15 | -$2.03 derived: net income ÷ weighted average shares · filed 2021-03-15 | -$2.56 derived: net income ÷ weighted average shares · filed 2021-03-15 |
| 2018-12-31 | -$0.63 10-K · filed 2020-03-12 | -$1.18 derived: net income ÷ weighted average shares · filed 2021-03-15 | -$1.71 derived: net income ÷ weighted average shares · filed 2021-03-15 | -$2.25 10-K · filed 2021-03-15 |
| 2018-09-30 | -$0.55 10-K · filed 2020-03-12 | -$1.07 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$1.61 10-Q · filed 2019-11-12 | -$2.33 derived: net income ÷ weighted average shares · filed 2020-03-12 |
| 2018-06-30 | -$0.52 10-K · filed 2020-03-12 | -$1.06 10-Q · filed 2019-08-14 | -$1.79 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2.52 derived: net income ÷ weighted average shares · filed 2020-03-12 |
| 2018-03-31 | -$0.54 10-K · filed 2020-03-12 | -$1.30 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2.07 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2.73 derived: net income ÷ weighted average shares · filed 2020-03-12 |
| 2017-12-31 | -$0.84 10-K · filed 2019-03-13 | -$1.63 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2.29 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2.88 10-K · filed 2020-03-12 |
| 2017-09-30 | -$0.79 10-K · filed 2019-03-13 | -$1.45 derived: net income ÷ weighted average shares · filed 2019-03-13 | -$1.99 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$0.66 10-K · filed 2019-03-13 | -$1.12 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$0.01 10-K · filed 2019-03-13 | |||
| 2016-12-31 | -$10.14 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |